Search

Issue
Title
Authors
New therapies for hormone-positive HER2-negative metastatic breast cancer with AKT signaling alterations: the Expert Panel Decision
Editorial B.
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
Kolyadina I.V., Ganshina I.P., Kuzmicheva S.V., Tekeeva A.I., Kolokolov J.D., Volkonskii M.V., Poddubnaya I.V.
Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study
Zhukova L.G., Bolotina L.V., Dvornichenko V.V., Fadeeva N.V., Ganshina I.P., Grechukhina K.S., Hasanova A.I., Kislov N.V., Kudryavtsev I.Y., Manikhas A.G., Musaeva N.E., Nizhegorodtseva A.A., Sadikova O.E., Sakaeva D.D., Snegovoy A.V., Stroyakovskiy D.L., Tjulandin S.A., Trishkina E.A., Vladimirova L.I., Volkov N.M., Kostalanova Y.V.
Modern ultrasound technologies in monitoring the effectiveness of chemotherapy for cervical cancer
Musaeva Z.R., Chekalova M.A., Mesheryakov A.A.
Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
Grechukhina K.S., Filonenko D.A., Sukhova M.V., Zhukova L.G.
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.B.
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review
Kolyadina I.V.
Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women
Jackisch C., Llombart-Cussac A.
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Board E.
Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
Zhabina A.S., Moiseenko F.V., Volkov N.M., Abduloeva N.K., Moiseenko V.M.
Isolated metastatic lesion of hyoid bone in gastric cancer: A rare case
Ognerubov N.A., Antipova T.S.
Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
Board E.
First results of a multicenter, non-randomized, prospective phase II study of the efficacy and safety of induction therapy with pembrolizumab, cisplatin, and 5-fluorouracil in patients with unresectable squamous cell carcinoma of the oropharynx, hypopharynx and larynx
Stativko O.A., Pokataev I.A., Kravtsov S.A., Zhukova L.G., Stroyakovskiy D.L., Sabitov E.R., Kuzmina E.S., Feoktistova P.S., Antonova T.G., Lyadova M.A., Nosova M.V., Sydykova R.S., Lisitsyna K.N., Strelnikova T.B., Alizade G.R., Parts S.A., Dolov M.M., Tedeeva A.K., Galkin V.N.
Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
Board E.
1 - 14 of 14 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"